Create a free QxMD account to take advantage of the features offered by Read like saving your papers and creating collections.

Get Started

COMMENT

Drug discovery: inhibitors that activate

Karen Cichowski, Pasi A Jänne

Nature 2010 March 18, 464 (7287): 358-9

No abstract text is available yet for this article.

Full Text Links

Find Full Text Links for this Article

Discussion

You are not logged in. Sign Up or Log In to join the discussion.

Related Papers

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Georgia Hatzivassiliou, Kyung Song, Ivana Yen, Barbara J Brandhuber, Daniel J Anderson, Ryan Alvarado, Mary J C Ludlam, David Stokoe, Susan L Gloor, Guy Vigers, Tony Morales, Ignacio Aliagas, Bonnie Liu, Steve Sideris, Klaus P Hoeflich, Bijay S Jaiswal, Somasekar Seshagiri, Hartmut Koeppen, Marcia Belvin, Lori S Friedman, Shiva Malek Nature 2010 March 18, 464 (7287): 431-5

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Poulikos I Poulikakos, Chao Zhang, Gideon Bollag, Kevan M Shokat, Neal Rosen Nature 2010 March 18, 464 (7287): 427-30

Drug discovery: How melanomas bypass new therapy. David Solit, Charles L Sawyers Nature 2010 December 16, 468 (7326): 902-3

MEK and RAF inhibitors for BRAF-mutated cancers. Sarah Belden, Keith T Flaherty Expert Reviews in Molecular Medicine 2012, 14: e17

Resistance to MEK inhibitors: should we co-target upstream? Poulikos I Poulikakos, David B Solit Science Signaling 2011 March 29, 4 (166): pe16

Parsing out the complexity of RAF inhibitor resistance. Martin McMahon Pigment Cell & Melanoma Research 2011, 24 (2): 361-5

RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling. Melissa M McKay, Daniel A Ritt, Deborah K Morrison Current Biology: CB 2011 April 12, 21 (7): 563-8

RAF inhibitors activate the MAPK pathway by relieving inhibitory autophosphorylation. Matthew Holderfield, Hanne Merritt, John Chan, Marco Wallroth, Laura Tandeske, Huili Zhai, John Tellew, Stephen Hardy, Mohammad Hekmat-Nejad, Darrin D Stuart, Frank McCormick, Tobi E Nagel Cancer Cell 2013 May 13, 23 (5): 594-602

RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth. Yves Romeo, Julie Moreau, Pierre-Joachim Zindy, Marc Saba-El-Leil, Geneviève Lavoie, Farah Dandachi, Marine Baptissart, Katherine L B Borden, Sylvain Meloche, Philippe P Roux Oncogene 2013 June 13, 32 (24): 2917-2926

Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Piro Lito, Anna Saborowski, Jingyin Yue, Martha Solomon, Eric Joseph, Sunyana Gadal, Michael Saborowski, Edward Kastenhuber, Christof Fellmann, Kazuhiro Ohara, Kenji Morikami, Takaaki Miura, Christine Lukacs, Nobuya Ishii, Scott Lowe, Neal Rosen Cancer Cell 2014 May 12, 25 (5): 697-710

Make the most of Read.
Download the mobile app.

Want full text access to this paper?

Use Read by QxMD to access full text via your institution or open access sources.

Read also provides personalized recommendations to keep you up to date in your field.

Existing User

New to Read

Drug discovery: inhibitors that activate

Discussion

Related Papers

Want full text access to this paper?

Save your favorite articles in one place with a free QxMD account.

Read

Search Tips